Submit Deal

Announced

28 May 2024

Completed

9 Sep 2024

Asahi Kasei completed the acquisition of Calliditas Therapeutics for $1.1bn.

Synopsis

Asahi Kasei, a multinational Japanese chemicals company, completed the acquisition of Calliditas Therapeutics, a commercial stage biopharmaceutical company, for $1.1bn.

Principals

target

Calliditas Therapeutics

bidder

Asahi Kasei Corporation

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Seller Team (12)

renée aguiar-lucander

CEO at CALLIDITAS THERAPEUTICS

Manager

target

Deals

£ 902 M

Total Value

fredrik carl johansson

CFO at CALLIDITAS THERAPEUTICS

Manager

target

Deals

£ 902 M

Total Value

dale raine

Managing Director & Co-Head European Healthcare at Lazard

Financial Advisor

target

Deals

£ 9.74 B

Total Value

elmar schnee

Chairman of the Board of Directors at CALLIDITAS THERAPEUTICS

Manager

target

Deal

£ 823 M

Total Value

asa hillsten

Head of IR & Sustainability at CALLIDITAS THERAPEUTICS

Manager

target

Deal

£ 823 M

Total Value

victor kastensson

Director at Lazard

Financial Advisor

target

Deals

£ 1.45 B

Total Value

phillip r. mills

Partner at Davis Polk & Wardwell

Advisor Lawyer

target

Deals

£ 179.07 B

Total Value

kristy choi

Associate at Davis Polk & Wardwell

Advisor Lawyer

target

Deals

£ 2.88 B

Total Value

jonathan klein

Partner at DLA Piper

Lawyer

target

Deals

£ 22.09 B

Total Value

paolo morante

Partner at DLA Piper

Lawyer

target

Deals

£ 14.75 B

Total Value

ting xiao

Partner at DLA Piper

Lawyer

target

Deal

£ 823 M

Total Value

benjamin vafaeian

Senior Associate at Vinge

Lawyer

target

Deal

£ 823 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy